Boule Diagnostics AB (publ) (BDABF)
- Previous Close
3.5100 - Open
3.5100 - Bid --
- Ask --
- Day's Range
3.5100 - 3.5100 - 52 Week Range
3.5100 - 7.8400 - Volume
2,000 - Avg. Volume
0 - Market Cap (intraday)
136.304M - Beta (5Y Monthly) 0.53
- PE Ratio (TTM)
18.47 - EPS (TTM)
0.1900 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date May 6, 2022
- 1y Target Est
--
Boule Diagnostics AB (publ) develops, manufactures, and markets instruments and consumable products for blood diagnostics in the United States of America, Asia, Eastern Europe, Latin America, Western Europe, Africa, and the Middle East. It provides hematology analyzers, reagents, controls, and calibrators, under the Swelab, Medonic, and Quintus brands; and veterinary hematology and clinical chemistry analyzer systems, as well as reagents and panels under the Exigo brand. The company serves small and medium-sized hospitals, clinics, laboratories, and veterinary clinics, and other diagnostics companies. The company was founded in 1956 and is headquartered in Spånga, Sweden.
www.boule.comRelated News
Performance Overview: BDABF
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BDABF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BDABF
Valuation Measures
Market Cap
35.05M
Enterprise Value
46.82M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
0.08
Enterprise Value/EBITDA
0.71
Financial Highlights
Profitability and Income Statement
Profit Margin
4.37%
Return on Assets (ttm)
3.59%
Return on Equity (ttm)
5.33%
Revenue (ttm)
571.33M
Net Income Avi to Common (ttm)
24.98M
Diluted EPS (ttm)
0.1900
Balance Sheet and Cash Flow
Total Cash (mrq)
37.28M
Total Debt/Equity (mrq)
34.98%
Levered Free Cash Flow (ttm)
-29.56M